Amy Ko Elevated to Fiduciary Trust International’s Regional Managing Director for Northern California
Firm Continues Focusing on Growth in Vital Region SAN MATEO, Calif.–(BUSINESS WIRE)–Fiduciary Trust International, a…
News
Keysight’s Battery Test Solution Accelerates Scania’s Heavy Transport Electrification
Scania establishes a battery laboratory with Keysight’s Scienlab Battery Test Solutions SANTA ROSA, Calif. &…
Dorsey’s Phoenix Office Launches Real Estate Practice
Firm adds priority practice area with four Phoenix market real estate lawyers PHOENIX–(BUSINESS WIRE)–International law…
Analytics Insight Announces ‘Top 10 Impactful CDIOs of 2022’
SAN JOSE, Calif. & HYDERABAD, India–(BUSINESS WIRE)–#CDIO–Analytics Insight has named ‘Top 10 Impactful CDIOs of…
Phison and Cigent Deliver Advanced Cybersecurity Protection in Storage Controllers and Firmware
“Cigent Secure SSD™ Ready” program to combat sophisticated threats and safeguard storage products, vulnerable endpoints,…
Mountain Valley MD Successfully Completes Pre-Clinical Pharmacokinetic Study For Soluvec™1%
TORONTO, June 27, 2022 (GLOBE NEWSWIRE) — Mountain Valley MD Holdings Inc. (the “Company” or…
Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome
NEWTON, Mass., June 27, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a clinical…
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on…
SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial
– No Dose-Limiting Toxicities Observed in Lymphoma and Acute Myeloid Leukemia Patients at All Dose…
Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments
Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint Inhibitors BRIDGEWATER, N.J., June…
Noema Pharma Announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b Study of PDE10A Inhibitor Gemlapodect (NOE-105) in Childhood Onset Fluency Disorder
Efficacy and safety study evaluating gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also…
Enzyvant Receives 2022 Rare Impact Industry Innovation Award from the National Organization for Rare Disorders (NORD) for Novel, Tissue-Based Therapy to Treat Ultra-Rare, Life-Threatening Pediatric Condition
Company honored for its work on RETHYMIC® (allogeneic processed thymus tissue-agdc), a one-time, treatment for…
High-Quality Botanical Ingredient Producer Linnea SA Celebrates 40 Years of Innovation
RIAZZINO, Switzerland, June 27, 2022 (GLOBE NEWSWIRE) — Linnea SA (“Linnea” or “the Company”), is…
Cidara Therapeutics to Host Research and Development Day
Virtual panel discussion will highlight the company’s Cloudbreak® platform and its potential advantages in oncology…
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM
BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company…
Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer
SYDNEY, AUSTRALIA, June 27, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”…
Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022
CRANBURY, N.J., June 27, 2022 (GLOBE NEWSWIRE) — Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”),…
Cronos Group Partners with Geocann to Leverage VESIsorb® Delivery Technology for Faster Absorption
TORONTO, June 27, 2022 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or…
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations…
BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers
– BBP-711 led to near complete inhibition of glycolate oxidase throughout the dosing period and…